Endocrinologia Japonica
Online ISSN : 2185-6370
Print ISSN : 0013-7219
ISSN-L : 0013-7219
Clinical and Pharmacological Aspects of Growth Hormone Replacement Therapy
J. SANDAHL CHRISTIANSENJ. O. L. JØRGENSENA. FLYVBJERGL. THUESENK. W. KASTRUPH. ORSKOV
Author information
JOURNAL FREE ACCESS

1987 Volume 34 Issue Supplement Pages 101-106

Details
Abstract
Replacement therapy with human growth hormone (hGH) in growth hormone (GH) deficient children was introduced by Raben in 1958 (1). Since then and until recently the proper treatment was considered to beintramuscular (i. m.) hGH injections twice or three times weekly. Various dosages have been proposed but a weekly dose of about 12 IU hGH has usually been recommended, partly because of shortage of supplies.
The subcutaneous (s. c.) route of administration was previously avoided because of putative enhancement of antibody formation (2). However, the introduction of highly purified hGH preparations led made us suggest that s. c. hGH replacement therapy was a safe and convenient alternative.(3).
Recombinant-DNA technology has resulted in production of biosynthetic growth hormone (B-hGH) carrying the native aminoacid sequence. Provided that the new B-hGH preparations prove safe there shall be no problems from shortage of supplies i.n the future. This will enable us to further optimize hGH replacement therapy to GH-deficient children, and also to consider new indications for hGH treatment.
The present review deals with the pharmacokinetic, metabolic and clinical aspects of s. c. hGH replacement therapy-and furthermore discusses acute cardiac effects of hGH administration.
Content from these authors
© The Japan Endocrine Society
Previous article Next article
feedback
Top